Eye Diseases
4
Pipeline Programs
6
Companies
5
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
6 companies ranked by most advanced pipeline stage
AlconFORT WORTH, TX
1 program1
Anecortave Acetate Sterile Suspension, 6 mg/mLPhase 21 trial
Active Trials
AB
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
GlaukosiStent
AlconAnecortave Acetate Sterile Suspension, 6 mg/mL
LENZ TherapeuticsAceclidine + Brimonidine
Active BiotechLaquinimod
T-TherapeuticsDREAM OCT
Clinical Trials (5)
Total enrollment: 70 patients across 5 trials
Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)
Start: May 2009Est. completion: Sep 2012
Phase 4Completed
Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation
Start: Dec 2005Est. completion: Jul 200970 patients
Phase 2Completed
Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia
Start: Jul 2023Est. completion: Oct 2023
Phase 1Completed
A Study of Laquinimod Eye-drops in Healthy Participants
Start: Dec 2021Est. completion: Jan 2023
Phase 1Completed
Swept Source OCT Imaging With the DREAM VG-OCT
Start: Oct 2023Est. completion: Oct 2024
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
6 companies competing in this space